ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-14
DOI
10.1038/s41388-019-1001-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
- (2018) Jeffrey S. Ross et al. CANCER
- Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer
- (2018) Toni M. Brand et al. CANCER RESEARCH
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- (2018) Katherine A. Hoadley et al. CELL
- Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
- (2018) Loic Verlingue et al. EUROPEAN JOURNAL OF CANCER
- GenomicERBB2/ERBB3mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
- (2018) Maolan Li et al. GUT
- Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
- (2018) Jonathan M Loree et al. JNCI-Journal of the National Cancer Institute
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating HER3 mutations in breast cancer
- (2018) Rosalin Mishra et al. Oncotarget
- Exome-wide somatic mutation characterization of small bowel adenocarcinoma
- (2018) Ulrika A. Hänninen et al. PLoS Genetics
- Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
- (2018) Jonathan M Loree et al. JNCI-Journal of the National Cancer Institute
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
- (2018) Nicole Michael Frazier et al. ONCOGENE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Accelerating Discovery of Functional Mutant Alleles in Cancer
- (2017) Matthew T. Chang et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Genomic Profiling of Small-Bowel Adenocarcinoma
- (2017) Alexa B. Schrock et al. JAMA Oncology
- Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
- (2016) Noura J. Choudhury et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Characterization of Primary Invasive Lobular Breast Cancer
- (2016) Christine Desmedt et al. JOURNAL OF CLINICAL ONCOLOGY
- A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia
- (2016) E M Braunstein et al. LEUKEMIA
- COSMIC: somatic cancer genetics at high-resolution
- (2016) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas
- (2016) Gabrielle Deniziaut et al. Oncotarget
- Response to dual HER2 blockade in a patient withHER3-mutant metastatic breast cancer
- (2015) F.-C. Bidard et al. ANNALS OF ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
- (2015) Matthew T Chang et al. NATURE BIOTECHNOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
- (2015) Ijeoma Umelo et al. Oncotarget
- Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
- (2015) Nadège Gaborit et al. Human Vaccines & Immunotherapeutics
- Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway
- (2014) Maolan Li et al. NATURE GENETICS
- Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
- (2014) P. Littlefield et al. Science Signaling
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Carboxyl Group Footprinting Mass Spectrometry and Molecular Dynamics Identify Key Interactions in the HER2-HER3 Receptor Tyrosine Kinase Interface
- (2013) Timothy S. Collier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- erbB3 Is an Active Tyrosine Kinase Capable of Homo- and Heterointeractions
- (2013) M. P. Steinkamp et al. MOLECULAR AND CELLULAR BIOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells
- (2009) M. Narayan et al. CANCER RESEARCH
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- The ERBB3 receptor in cancer and cancer gene therapy
- (2008) G Sithanandam et al. CANCER GENE THERAPY
- The ErbB kinase domain: Structural perspectives into kinase activation and inhibition
- (2008) Ron Bose et al. EXPERIMENTAL CELL RESEARCH
- Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
- (2008) Amit Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started